George G Zhanel1,2, Heather J Adam1,3, Melanie R Baxter1, Jeff Fuller4,5, Kimberly A Nichol3, Andrew J Denisuik1, Alyssa R Golden1, Rachel Hink1, Philippe R S Lagacé-Wiens1,6, Andrew Walkty1,2,3, Michael R Mulvey1,7, Frank Schweizer1,8, Denice Bay1, Daryl J Hoban1,3, James A Karlowsky1,6. 1. Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Room 543-745 Bannatyne Avenue, Winnipeg, Manitoba, Canada. 2. Department of Medicine, Health Sciences Centre, 820 Sherbrook Street, Winnipeg, Manitoba, Canada. 3. Clinical Microbiology, Health Sciences Centre/Diagnostic Services, Shared Health, MS673-820 Sherbrook Street, Winnipeg, Manitoba, Canada. 4. Department of Pathology and Laboratory Medicine, Schulich School of Medicine and Dentistry, Western University, Victoria Hospital, Room B10-117, London, Ontario, Canada. 5. Division of Microbiology, London Health Sciences Centre, 800 Commissioners Road East, London, Ontario, Canada. 6. Clinical Microbiology, St. Boniface Hospital/Diagnostic Services, Shared Health Manitoba, L4025-409 Taché Avenue, Winnipeg, Manitoba, Canada. 7. National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba, Canada. 8. Department of Chemistry, University of Manitoba, 360 Parker Building, 144 Dysart Road, Winnipeg, Manitoba, Canada.
Abstract
OBJECTIVES: The CANWARD surveillance study was established in 2007 to annually assess the in vitro susceptibilities of a variety of antimicrobial agents against bacterial pathogens isolated from patients receiving care in Canadian hospitals. METHODS: 42 936 pathogens were received and CLSI broth microdilution testing was performed on 37 355 bacterial isolates. Limited patient demographic data submitted with each isolate were collated and analysed. RESULTS: Of the isolates tested, 43.5%, 33.1%, 13.2% and 10.2% were from blood, respiratory, urine and wound specimens, respectively; 29.9%, 24.8%, 19.0%, 18.1% and 8.2% of isolates were from patients in medical wards, emergency rooms, ICUs, hospital clinics and surgical wards. Patient demographics associated with the isolates were: 54.6% male/45.4% female; 13.1% patients aged ≤17 years, 44.3% 18-64 years and 42.7% ≥65 years. The three most common pathogens were Staphylococcus aureus (21.2%, both methicillin-susceptible and MRSA), Escherichia coli (19.6%) and Pseudomonas aeruginosa (9.0%). E. coli were most susceptible to meropenem and tigecycline (99.9%), ertapenem and colistin (99.8%), amikacin (99.7%) and ceftolozane/tazobactam and plazomicin (99.6%). Twenty-three percent of S. aureus were MRSA. MRSA were most susceptible to ceftobiprole, linezolid and telavancin (100%), daptomycin (99.9%), vancomycin (99.8%) and tigecycline (99.2%). P. aeruginosa were most susceptible to ceftolozane/tazobactam (98.3%) and colistin (95.0%). CONCLUSIONS: The CANWARD surveillance study has provided 10 years of reference antimicrobial susceptibility testing data on pathogens commonly causing infections in patients attending Canadian hospitals.
OBJECTIVES: The CANWARD surveillance study was established in 2007 to annually assess the in vitro susceptibilities of a variety of antimicrobial agents against bacterial pathogens isolated from patients receiving care in Canadian hospitals. METHODS: 42 936 pathogens were received and CLSI broth microdilution testing was performed on 37 355 bacterial isolates. Limited patient demographic data submitted with each isolate were collated and analysed. RESULTS: Of the isolates tested, 43.5%, 33.1%, 13.2% and 10.2% were from blood, respiratory, urine and wound specimens, respectively; 29.9%, 24.8%, 19.0%, 18.1% and 8.2% of isolates were from patients in medical wards, emergency rooms, ICUs, hospital clinics and surgical wards. Patient demographics associated with the isolates were: 54.6% male/45.4% female; 13.1% patients aged ≤17 years, 44.3% 18-64 years and 42.7% ≥65 years. The three most common pathogens were Staphylococcus aureus (21.2%, both methicillin-susceptible and MRSA), Escherichia coli (19.6%) and Pseudomonas aeruginosa (9.0%). E. coli were most susceptible to meropenem and tigecycline (99.9%), ertapenem and colistin (99.8%), amikacin (99.7%) and ceftolozane/tazobactam and plazomicin (99.6%). Twenty-three percent of S. aureus were MRSA. MRSA were most susceptible to ceftobiprole, linezolid and telavancin (100%), daptomycin (99.9%), vancomycin (99.8%) and tigecycline (99.2%). P. aeruginosa were most susceptible to ceftolozane/tazobactam (98.3%) and colistin (95.0%). CONCLUSIONS: The CANWARD surveillance study has provided 10 years of reference antimicrobial susceptibility testing data on pathogens commonly causing infections in patients attending Canadian hospitals.
Authors: James A Karlowsky; Melanie R Baxter; Alyssa R Golden; Heather J Adam; Andrew Walkty; Philippe R S Lagacé-Wiens; George G Zhanel Journal: J Clin Microbiol Date: 2021-09-08 Impact factor: 5.948
Authors: Graham W Cox; Brent P Avery; E Jane Parmley; Rebecca J Irwin; Richard J Reid-Smith; Anne E Deckert; Rita L Finley; Danielle Daignault; George G Zhanel; Michael R Mulvey; Amrita Bharat Journal: Antimicrob Agents Chemother Date: 2022-09-27 Impact factor: 5.938
Authors: Branden S J Gregorchuk; Shelby L Reimer; Carmine J Slipski; Kieran A Milner; Shannon L Hiebert; Daniel R Beniac; Timothy F Booth; George G Zhanel; Denice C Bay Journal: Sci Rep Date: 2022-07-15 Impact factor: 4.996
Authors: James A Karlowsky; Philippe R S Lagacé-Wiens; Nancy M Laing; Melanie R Baxter; Heather J Adam; George G Zhanel Journal: J Clin Microbiol Date: 2020-09-22 Impact factor: 5.948
Authors: Alyssa R Golden; Melanie R Baxter; James A Karlowsky; Laura Mataseje; Michael R Mulvey; Andrew Walkty; Denice Bay; Frank Schweizer; Philippe R S Lagace-Wiens; Heather J Adam; George G Zhanel Journal: JAC Antimicrob Resist Date: 2022-02-07
Authors: Lionel A Mandell; George G Zhanel; Coleman Rotstein; John Muscedere; Mark Loeb; Jennie Johnstone Journal: Open Forum Infect Dis Date: 2022-02-04 Impact factor: 3.835
Authors: James A Karlowsky; Andrew J Walkty; Melanie R Baxter; Heather J Adam; Philippe R S Lagacé-Wiens; Frank Schweizer; Denice Bay; Joseph P Lynch; Michael R Mulvey; George G Zhanel Journal: Microbiol Spectr Date: 2022-06-27
Authors: A Walkty; J A Karlowsky; P R S Lagacé-Wiens; A R Golden; M R Baxter; A J Denisuik; M McCracken; M R Mulvey; H J Adam; G G Zhanel Journal: JAC Antimicrob Resist Date: 2022-03-21